ANIP vs PAHC: stock comparison and AI forecast
Ani Pharmaceuticals Inc (ANIP) and Phibro Animal Health Corp (PAHC) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ANIP Ani Pharmaceuticals Inc
- Price
- $69.62 -17.0% · 6M
- Market Cap
- $1.60B
- P/E Ratio
- 12.3x
- Size
- small-cap
- AI Forecast
PAHC Phibro Animal Health Corp
- Price
- $39.43 -32.6% · 6M
- Market Cap
- $1.44B
- P/E Ratio
- 14.2x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ANIP is 1.1 times larger than PAHC by market capitalization ($1.60B against $1.44B).
- ANIP trades at 12.3 times trailing earnings, PAHC at 14.2 times.
- Over the last six months ANIP returned -17.0% and PAHC -32.6%.
- PAHC yields 1.35% in dividends; ANIP pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ANIP | PAHC |
|---|---|---|
| Market Cap | $1.60B | $1.44B |
| P/E Ratio | 12.28x | 14.16x |
| P/B Ratio | 2.51x | – |
| Dividend Yield | – | 1.35% |
| EPS | $5.67 | $2.50 |
| Book Value/Share | $27.75 | – |
| Revenue/Share | $0.68 | $37.95 |
| FCF/Share | $8.94 | $0.53 |
Profitability & Margins
| Metric | ANIP | PAHC |
|---|---|---|
| ROE | 18.3% | – |
| ROA | 7.5% | – |
| ROIC | 13.4% | – |
| Gross Margin | -2479.9% | 33.8% |
| Operating Margin | 1059.2% | 27.8% |
| Net Margin | 743.3% | – |
| EBT Margin | 1004.1% | 20.2% |
| Tax Rate | 26.0% | 26.6% |
Financial Health
| Metric | ANIP | PAHC |
|---|---|---|
| Current Ratio | 2.75x | 3.20x |
| Quick Ratio | 2.33x | 1.28x |
| D/E Ratio | 1.46x | – |
| Financial Leverage | 2.46x | – |
| Interest Coverage | 6.9x | 1.1x |
| Working Capital | $574M | $649M |
Cash Flow
| Metric | ANIP | PAHC |
|---|---|---|
| Operating Cash Flow | $229M | $86M |
| Free Cash Flow | $205M | $22M |
| Capital Spending | -$24M | -$64M |
| OCF Growth YoY | 34.2% | 11.6% |
| FCF Growth YoY | 31.8% | -54.2% |
| FCF/Sales | 1306.2% | 1.4% |
| CapEx/Sales | 151.9% | 4.2% |
Operational Efficiency
| Metric | ANIP | PAHC |
|---|---|---|
| Asset Turnover | 0.01x | – |
| Receivables Turnover | 0.1x | 7.0x |
| Inventory Turnover | 3.0x | 1.8x |
| Fixed Assets Turnover | 0.2x | 4.1x |
| Days Sales Outstanding | 7069 days | 53 days |
| Days Inventory | 123 days | 203 days |
| Payables Period | 67 days | 49 days |
| Cash Conversion Cycle | 7125 days | 207 days |
Income Statement
| Metric | ANIP | PAHC |
|---|---|---|
| Total Revenue | $16M | $1.54B |
| Operating Income | $166M | $193M |
| Net Income | $117M | – |
| R&D Expense | $51M | – |
| SG&A Expense | $343M | $328M |
| Cost of Goods Sold | $406M | $1.02B |
Dividend & Shareholder Information
| Metric | ANIP | PAHC |
|---|---|---|
| Dividends Per Share | – | $0.48 |
| Payout Ratio | – | 19.2% |
| Shares Outstanding | 23M | 41M |
| Net Income Growth | 282.0% | – |
| EPS Growth | 229.7% | 49.7% |
ANIP vs PAHC: stock comparison and AI forecast
Which is bigger, ANIP or PAHC?
ANIP is 1.1 times larger than PAHC by market capitalization ($1.60B against $1.44B).
Which is cheaper on earnings, ANIP or PAHC?
ANIP trades at 12.3 times trailing earnings, PAHC at 14.2 times.
Which stock performed better over the last six months, ANIP or PAHC?
Over the last six months ANIP returned -17.0% and PAHC -32.6%.
Which one does Intratio's AI model rank higher, ANIP or PAHC?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.